Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression

Fig. 5

Hymecromone decreases hyaluronan by downregulating hyaluronic acid synthases. a ELISA detected the hyaluronic acid level of culture medium in HEK293T and HUVEC treated with DMSO or hymecromone (200 μg/mL). The fold change of hyaluronic acid was normalized to DMSO. b RT-qPCR evaluated the mRNA levels of HAS1, HAS2, and HAS3 in HEK293T treated with DMSO or hymecromone (200 μg/mL). c RT-qPCR evaluated the mRNA levels of HAS1, HAS2, and HAS3 in HUVEC treated with DMSO or hymecromone (200 μg/mL). All experiments were repeated independently in triplicate. Data are presented by mean ± SD. The significant difference was confirmed by unpaired t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant

Back to article page